Merz swoops into Obagi deal with $385M bid, topping Valeant

These days, dermatology is the belle of the ball. Drugmakers have been wooing small players in the skin-treatment field, and just last month, Valeant Pharmaceuticals ($VRX) announced that it had agreed to buy Obagi Medical for $345 million.

But now, Merz Pharma has trumped that bid. Frankfurt-based Merz offered $22 per share for Obagi, topping Valeant's $19.75 bid. The Merz offer is worth about $385 million.

In Merz's letter to Obagi, the German company said it had been in "ongoing discussions" about a deal when Valeant swooped in with a bid. Merz says it didn't have the chance to put in a higher offer before the Valeant deal was announced. So, it's releasing this new bid publicly, to give Obagi shareholders the chance to decide.

"[T]hroughout this entire process we have preferred to work with you privately to consummate a transaction," Merz CEO Philip Burchard and VP Hans-Jörg Bergler wrote. "[W]e are now compelled to pursue a different approach … [and] believe that it is best to provide this letter to you and make it public at the same time."

Does Valeant come back with a higher bid, as Obagi shareholders seem to think? The company's stock rose past $22, to $22.79 per share, after Merz's bid was announced. Valeant itself isn't talking yet. But its CEO J. Michael Pearson is a notorious cheapskate, and dermatology is full of small companies ripe for consolidation.

Just consider the pace of dermatology-related deals in recent months. Novartis' ($NVS) generics unit, Sandoz, bought U.S.-based Fougera Pharmaceuticals last year for $1.5 billion, instantly becoming the biggest in the field. Then Valeant paid $2.6 billion for Medicis. In November, India's Sun Pharma nabbed DUSA Pharmaceuticals for about $230 million, and then Perrigo ($PRGO) spent $45 million to buy the 81.5% of Cobrek Pharmaceuticals that it didn't already own.

- see the Merz release

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.